Examining KLHL6 in the tumor tissues of patients treated with these regimens could reveal a biomarker role for KLHL6 mutations and KLHL6GC+ phenotype to predict responses besides being a prognostic marker in the ABC DLBCL. Here, KLHL6 is linked to aneurysmal bone cyst.